All In Biotech

Drug Trial Radar · NCT07128615

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 405 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

405

Actual

Start

Sep 4, 2025

Primary completion

Jan 28, 2026

Study completion Dec 29, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority; Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies
First posted
Aug 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).

Conditions

  • Influenza A

Interventions

  • AZD4117Biological

    Intramuscular (IM) injection

  • AZD5315Biological

    IM injection

  • PlaceboOther

    IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with immediate unsolicited adverse events (AE)Time frame: Within 30 minutes after dosing
  2. Percentage of participants with injection site and systemic solicited adverse reactions (AR)Time frame: Through 7 days after dosing
  3. Percentage of participants with unsolicited AETime frame: Through 28 days after the last dose
  4. Percentage of participants with serious adverse events (SAE)Time frame: Through 12 months after the last dose
  5. Percentage of participants with medically attended adverse events (MAAE)Time frame: Through 12 months after the last dose
  6. Percentage of participants with adverse events of special interest (AESI)Time frame: Through 12 months after the last dose
  7. Proportion of participants achieving ≥ 1:40 HAI titer post-IMP administrationTime frame: Day 58
  8. Proportion of participants achieving seroconversion post-IMP administrationTime frame: Day 58

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Long Beach, California

  • Research Site

    Rolling Hills Estates, California

  • Research Site

    Miami Lakes, Florida

  • Research Site

    Stockbridge, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Lenexa, Kansas

  • Research Site

    Kansas City, Missouri

  • Research Site

    Omaha, Nebraska

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Edmond, Oklahoma

  • Research Site

    North Charleston, South Carolina

  • Research Site

    Austin, Texas

  • Research Site

    West Jordan, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.